Miguel Cordova Delgado

Miguel Cordova completed his PhD in Pharmacology at the University of Chile. His training spans biochemistry, pharmacology, bioinformatics, and data analysis. As an undergraduate, he studied the mechanisms of novel anticancer compounds for breast cancer, gaining expertise in organic chemistry and cell biology. His doctoral research focused on pharmacogenetic markers linked to toxicity in gastric cancer patients treated with platinum/fluoropyrimidines-based therapy. He developed a predictive model integrating genetic variants in key pharmacokinetic/pharmacodynamic genes with clinical factors, achieving strong performance in identifying patients at risk for severe toxicity. His postdoctoral work aims to understand how germline variants contribute to severe adverse drug reactions in pediatric cancer patients undergoing chemotherapy, with the goal of improving drug safety and personalized treatment in children.